Huntington National Bank Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Huntington National Bank reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.4% in the second quarter, according to its most recent filing with the SEC. The fund owned 378 shares of the biopharmaceutical company’s stock after selling 122 shares during the period. Huntington National Bank’s holdings in Regeneron Pharmaceuticals were worth $198,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of REGN. PGGM Investments lifted its holdings in Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after buying an additional 51,900 shares in the last quarter. Founders Capital Management LLC grew its stake in Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after acquiring an additional 538 shares in the last quarter. Sepio Capital LP increased its position in shares of Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after acquiring an additional 842 shares during the period. Generate Investment Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $6,300,000. Finally, Bellecapital International Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 32.7% during the second quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock valued at $13,389,000 after acquiring an additional 6,283 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $657.53 on Friday. The stock’s 50-day moving average is $588.03 and its 200 day moving average is $568.16. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $834.42. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. The company has a market cap of $69.69 billion, a P/E ratio of 15.75, a PEG ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period in the prior year, the firm posted $12.46 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Analyst Ratings Changes

Several brokerages recently issued reports on REGN. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 29th. Weiss Ratings reissued a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, October 23rd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $796.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.